Forsigtighed bør udvises under samtidig administration af posaconazol og CYP3A4 substrater indgivet intravenøst, og der kan være behov for at dosen af CYP3A4 substratet reduceres.
Caution is advised during co- administration of posaconazole with CYP3A4 substrates administered intravenously and the dose of the CYP3A4 substrate may need to be reduced.